Evidence map›Paper›PMID 35887914›Full record

ArticleJournal of clinical medicine2022

Impact of CFTR Modulators on Beta-Cell Function in Children and Young Adults with Cystic Fibrosis.

Claudia Piona, Enza Mozzillo, Antonella Tosco, Sonia Volpi, Francesco Maria Rosanio, Chiara Cimbalo, Adriana Franzese, Valeria Raia, Chiara Zusi, Federica Emiliani and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The impact of elexacaftor-tezacaftor-ivacaftor on cardiometabolic risk factors: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Claudia PionaDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.
Enza MozzilloRegional Pediatric Diabetes Center, Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, 80131 Naples, Italy.
Antonella ToscoRegional Pediatric Cystic Fibrosis Center, Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, 80131 Naples, Italy.
Sonia VolpiCystic Fibrosis Unit, Regional Center for Cystic Fibrosis, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.
Francesco Maria RosanioRegional Pediatric Diabetes Center, Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, 80131 Naples, Italy.ORCID 0000-0002-1369-0691
Chiara CimbaloRegional Pediatric Cystic Fibrosis Center, Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, 80131 Naples, Italy.
Adriana FranzeseRegional Pediatric Diabetes Center, Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, 80131 Naples, Italy.
Valeria RaiaRegional Pediatric Cystic Fibrosis Center, Department of Translational Medical Sciences, Section of Pediatrics, Federico II University of Naples, 80131 Naples, Italy.
Chiara ZusiDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.ORCID 0000-0002-4059-4160
Federica EmilianiDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.
Maria Linda BoselliDepartment of Medicine, Section of Endocrinology, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.
Maddalena TrombettaDepartment of Medicine, Section of Endocrinology, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.
Riccardo Crocina BonadonnaDepartment of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
Marco CipolliCystic Fibrosis Unit, Regional Center for Cystic Fibrosis, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.
Claudio MaffeisDepartment of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, 37126 Verona, Italy.ORCID 0000-0002-3563-4404
Azienda Ospedaliera Universitaria Integrata Verona · ITFederico II University Hospital · ITUniversity of Parma · IT

Funding

Lega Italiana Fibrosi Cistica (LIFC) of Veneto Region naMIUR PRIN 2015373Z39004University of Parma FIL grantUniversity of Verona FURMAF2019
6 · The paper itself

Abstract

backgroundTo date, no consistent data are available on the possible impact of CFTR modulators on glucose metabolism. The aim of this study was to test the hypothesis that treatment with CFTR modulators is associated with an improvement in the key direct determinants of glucose regulation in children and young adults affected by Cystic Fibrosis (CF).

methodsIn this study, 21 CF patients aged 10-25 underwent oral glucose tolerance test (OGTT) before and after 12-18 months of treatment with Lumacaftor/Ivacaftor or Elexacaftor-Ivacaftor-Tezacaftor. β-cell function (i.e., first and second phase of insulin secretion measured as derivative and proportional control, respectively) and insulin clearance were estimated by OGTT mathematical modelling. Insulin sensitivity was estimated by the Oral Glucose Sensitivity Index (OGIS). The dynamic interplay between β-cell function, insulin clearance and insulin sensitivity was analysed by vector plots of glucose-stimulated insulin bioavailability vs. insulin sensitivity.

resultsNo changes in glucose tolerance occurred after either treatment, whereas a significant improvement in pulmonary function and chronic bacterial infection was observed. Beta cell function and insulin clearance did not change in both treatment groups. Insulin sensitivity worsened in the Lumacaftor/Ivacaftor group. The analysis of vector plots confirmed that glucose regulation was stable in both groups.

conclusionsTreatment of CF patients with CFTR modulators does not significantly ameliorate glucose homeostasis and/or any of its direct determinants.

Indexed as

cftr modulatorscystic fibrosiselexacaftor-ivacaftor-tezacaftorglucose metabolisminsulin clearanceinsulin sensitivitylumacaftor/ivacaftororal glucose tolerance testβ-cell function

Identifiers

PMID35887914
PMCPMC9319690
OpenAlexW4285732011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.